Journal of Medicinal Chemistry Submission Guide

Source: Journal of Medicinal Chemistry on ACS, Clarivate 2026 JCR release, accessed April 2026; article types, portal, abstract and timing medians checked against the ACS author guidelines and ACS Journal Metrics on 2026-10-09.

This is the JMC-specific editorial detail authors most often miss:

The journal's scope statement says its primary objective is to publish studies that contribute to an understanding of the relationship between molecular structure and biological activity or mode of action. In practice, a strong manuscript includes:

1. SAR table or analysis showing structural variants and biological activity

1. Biological evaluation with appropriate assays (typically in vitro, often in vivo)

1. Lead-optimization narrative justifying the path from initial hits to optimized compounds

The strategic implication: the author guidelines say applications of existing computational methods are not considered without original experimental data that assess the computational predictions, and routine extensions of existing series that do not add significantly to a basic understanding of the SAR will normally not be considered. Authors should ensure SAR data, biological assays, and lead-optimization narrative are complete before submission.

Three operational signals govern editorial assessment:

1. SAR substance. The scope statement says routine extensions of existing series that do not utilize novel chemical or biological approaches, or do not add significantly to a basic understanding of the SAR of the series, will normally not be considered, and the guidelines do not consider applications of existing computational methods without original experimental data that assess the predictions.

2. Drug-discovery framing. The work must contribute to drug-discovery understanding, not just chemistry method development.

3. Methodological rigor. Synthesis, characterization, biological evaluation, and (where applicable) ADMET data must be top-tier.

Recent JMC issues span:

• Targeted protein degradation (PROTACs, molecular glues)

• Covalent and irreversible inhibitors

• Allosteric modulators and binding-site discovery

• Antibiotics and antimicrobial discovery

• Oncology drug discovery (kinase inhibitors, etc.)

• CNS drug discovery

• AI/ML in medicinal chemistry

• Macrocycles and beyond-rule-of-5 chemical space

For specific recent papers and DOIs, see JMC on ACS.

• Median days from submission to first editorial decision without peer review: 6 (ACS Journal Metrics, 2025 data)

• Median days from submission to first decision with peer review: 28.9 (ACS Journal Metrics, 2025 data)

• Median days from submission to acceptance, including author revision time: 93 (ACS Journal Metrics, 2025 data)

• Revision deadlines in the author guidelines: within 7 days of a formatting-only revision request, 30 days of a minor revision request, 60 days of a major revision request, and 180 days of a Reject & Resubmit request

• Median days from acceptance to ASAP publication: 9.9 (ACS Journal Metrics, 2025 data)

Get the mechanics from the journal, then stress-test the package yourself. The review tells you whether your paper clears the Journal of Medicinal Chemistry fit check before upload, especially around sAR data thin or absent, pure-computational work without biological validation, and wrong medicinal-chemistry venue chosen. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Three patterns generate the most consistent rejections.

SAR data thin or absent

JMC requires substantive structure-activity-relationship analysis, not a single active compound. In our pre-submission review work, the most common version of this miss is a manuscript reporting one promising molecule with potent activity but only a handful of analogs, so the structural logic behind the potency stays implicit. The fix is to include an SAR table that maps systematic structural variants to matched biological-activity data, and to narrate why each modification was made. Reviewers read that table as evidence the lead-optimization reasoning is real rather than retrospective.

Check sar data thin or absent before submitting to Journal of Medicinal Chemistry →

Pure-computational work without biological validation

The JMC author guidelines say applications of existing computational methods are not considered without original experimental data that assess the computational predictions, so docking, molecular-dynamics, or de novo design results without any measured in vitro activity are unlikely to clear review. In our pre-submission review work, we see strong computational manuscripts stall here simply because the predicted binders were never tested in an assay. The fix is honest: route purely computational work to specialist venues such as J. Chem. Inf. Model. or Mol. Pharmaceutics, and submit to JMC only once biological validation backs the computational claim. Even a small, well-controlled assay set that confirms the predicted activity moves the manuscript across the bar.

Check pure computational work without biological validation before submitting to Journal of Medicinal Chemistry →

Wrong medicinal-chemistry venue chosen

JMC competes with EJMC, ACS Med Chem Letters, BMC, and computational specialists. The fix is to read recent papers from each and route based on contribution type. A JMC manuscript readiness check can identify whether SAR substance, drug-discovery framing, and biological-evaluation rigor align before submission.

Check wrong medicinal chemistry venue chosen before submitting to Journal of Medicinal Chemistry →

JMC requires these at first submission:

• main manuscript file submitted through the ACS Publishing Center (no document template is required)

• cover letter including the manuscript title, a short description of the research, explicit explanation of why it is appropriate for JMC, and the journal purity statement "All compounds are >95% pure by HPLC analysis." (the cover letter is the primary editorial-fit signal since the Author Submission Checklist is no longer required)

• graphical TOC summary (required; supplied as the last page of the manuscript and labeled "Table of Contents graphic")

• structure-activity-relationship (SAR) analysis with appropriate biological evaluation, because the scope statement centers on structure-activity relationships (in vitro typically; in vivo where the lead-optimization stage justifies it)

• author byline with full names and affiliations (a validated ORCID iD is required from the submitting author when submitting a revision and strongly encouraged for all authors)

• author contributions statement, for example "These authors contributed equally."

• conflict-of-interest disclosure covering financial relationships, industry consulting, equity, licensing, and any pharma-company affiliations

• ethics statement for any animal protocols (IACUC approval) or human-subjects work

• chemical-characterization data per the author guidelines: spectral data sufficient to identify each new compound (generally a listing of 1H or 13C NMR peaks, assigned when NMR is the basis of identification; HRMS may be supplied as an additional criterion), purity of at least 95% for all tested compounds (HPLC, combustion analysis, or qHNMR), and the melting point or range for solids

• Supporting Information as a separate file or files, submitted at the same time as the manuscript, with all spectra, full crystallographic data where applicable, and additional biological-evaluation tables

• $4,500 USD (CC BY) or $4,000 USD (CC BY-NC-ND) APC for the ACS gold open-access option (standard pricing in ACS hybrid journals, ACS pricing tables read 2026-10-09; subscription publication has no APC; many institutional ACS Read+Publish agreements cover the fee)

• disclosure of any AI tool use for text or image generation, placed in the Acknowledgments section per ACS policy

• for revised submissions, the revised manuscript uploaded within the revision deadline (7 days for a formatting-only request, 30 days for minor, 60 days for major, and 180 days for Reject & Resubmit)

For JMC submissions, a common artifact-related issue in our pre-submission review work is computational drug-design submissions without biological validation. The author guidelines do not consider applications of existing computational methods without original experimental data that assess the predictions; submissions reporting docking, MD simulation, or de novo design without any in vitro activity data are better suited to specialist computational venues (J. Chem. Inf. Model., Mol. Pharmaceutics). Even biological-evaluation work that uses borrowed assays from collaborators (rather than the authors' own lab) needs explicit attribution and validation against the authors' SAR claims.

Run a Journal of Medicinal Chemistry pre-submission readiness check before clicking submit to verify the package meets the journal's SAR-with-biological-validation bar.

ACS publishes median days for Journal of Medicinal Chemistry rather than a stage-by-stage schedule. In ACS Journal Metrics (2025 data, read 2026-10-09) the medians are 6 days from submission to first editorial decision without peer review, 28.9 days from submission to first decision for manuscripts that received peer review, 93 days from submission to acceptance (including the time authors take to revise), and 9.9 days from acceptance to ASAP publication (including the time to review and approve proofs). The stages below follow the order ACS describes them; the day counts are those medians, not guarantees.

• Pre-screening: The Journal Editorial Office checks the manuscript for proper formatting and other requirements. The cover letter must say why the work is appropriate for JMC, and authors may suggest Associate Editor(s), although because of manuscript workload the desired Editor may not be assigned.

• Editor assessment: ACS says the Editor-in-Chief, Executive Editors, or Development Editors assess the manuscript for scope, scientific merit and significance. If a submission is declined, the editors might suggest a transfer to another ACS journal. The published median to a first editorial decision without peer review is 6 days.

• Peer review: An Associate Editor evaluates the manuscript and selects experts for peer review, and ACS's publishing-process page says a manuscript sent for review is reviewed by at least three peers. The published median to a first decision for manuscripts that received peer review is 28.9 days.

• Decision and revision: Revisions are due within 7 days of a formatting-only request, 30 days of a minor revision request, 60 days of a major revision request, and 180 days of a Reject & Resubmit request. The published median from submission to acceptance is 93 days, which includes author revision time.

• Is Journal of Medicinal Chemistry a good journal?

• European Journal of Medicinal Chemistry Submission Guide

• ACS Medicinal Chemistry Letters Submission Guide

Last verified: 2026-10-09 against the JMC journal pages, the ACS author guidelines, and ACS Journal Metrics.